These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32404570)

  • 1. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders.
    Tokuhira M; Tanaka Y; Takahashi Y; Kimura Y; Tomikawa T; Anan T; Watanabe J; Sagawa M; Higashi M; Momose S; Amano K; Tabayashi T; Nakaseko R; Tamaru JI; Kizaki M
    J Clin Exp Hematop; 2020 Jun; 60(2):41-50. PubMed ID: 32404570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression.
    Takanashi S; Aisa Y; Ito C; Arakaki H; Osada Y; Amano Y; Hirano M; Nakazato T
    Rheumatol Int; 2017 Oct; 37(10):1629-1633. PubMed ID: 28676912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Methotrexate-associated lymphoproliferative disorders: clinical aspects].
    Tokuhira M; Kizaki M
    Rinsho Ketsueki; 2019; 60(8):932-943. PubMed ID: 31484893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate.
    Saito S; Kaneko Y; Yamaoka K; Tokuhira M; Takeuchi T
    Rheumatology (Oxford); 2017 Jun; 56(6):940-946. PubMed ID: 28165538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal.
    Inui Y; Matsuoka H; Yakushijin K; Okamura A; Shimada T; Yano S; Takeuchi M; Ito M; Murayama T; Yamamoto K; Itoh T; Aiba K; Minami H
    Leuk Lymphoma; 2015; 56(11):3045-51. PubMed ID: 25721751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders.
    Tokuhira M; Tamaru JI; Kizaki M
    J Clin Exp Hematop; 2019; 59(2):72-92. PubMed ID: 31257348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
    Nakano K; Saito K; Nawata A; Hanami K; Kubo S; Miyagawa I; Fujino Y; Nakayamada S; Tanaka Y
    Mod Rheumatol; 2021 Jan; 31(1):94-100. PubMed ID: 32159414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
    Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
    Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders.
    Tokuhira M; Saito S; Suzuki K; Higashi M; Momose S; Shimizu T; Mori T; Kimura Y; Amano K; Okamoto S; Takeuchi T; Tamaru JI; Kizaki M
    Leuk Lymphoma; 2019 Oct; 60(10):2508-2515. PubMed ID: 30947579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
    Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
    Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
    Harada T; Iwasaki H; Muta T; Urata S; Sakamoto A; Kohno K; Takase K; Miyamura T; Sawabe T; Asaoku H; Oryoji K; Fujisaki T; Mori Y; Yoshimoto G; Ayano M; Mitoma H; Miyamoto T; Niiro H; Yamamoto H; Oshiro Y; Miyoshi H; Ohshima K; Takeshita M; Akashi K; Kato K
    Br J Haematol; 2021 Jul; 194(1):101-110. PubMed ID: 33822354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate-associated orbital lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report.
    Kobayashi Y; Kimura K; Fujitsu Y; Shinkawa K; Muta H; Sonoda KH
    Jpn J Ophthalmol; 2016 May; 60(3):212-8. PubMed ID: 27018050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders.
    Yamakawa N; Fujimoto M; Kawabata D; Terao C; Nishikori M; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Ohmura K; Fujii T; Kitano T; Kondo T; Yurugi K; Miura Y; Maekawa T; Saji H; Takaori-Kondo A; Matsuda F; Haga H; Mimori T
    J Rheumatol; 2014 Feb; 41(2):293-9. PubMed ID: 24334644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
    Salloum E; Cooper DL; Howe G; Lacy J; Tallini G; Crouch J; Schultz M; Murren J
    J Clin Oncol; 1996 Jun; 14(6):1943-9. PubMed ID: 8656264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report.
    Toyonaga H; Fukushima M; Shimeno N; Inokuma T
    BMC Gastroenterol; 2019 Apr; 19(1):62. PubMed ID: 31023238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis.
    Tanaka K; Ichikawa A; Umezawa N; Yamamoto K; Yoshifuji K; Okada K; Nogami A; Umezawa Y; Nagao T; Sakashita C; Mori T; Tohda S; Koike R; Yasuda S; Yamamoto M
    Cancer Sci; 2023 Sep; 114(9):3719-3727. PubMed ID: 37365854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct decrease in peripheral lymphocytes in EBER-positive cases of MTX-LPD.
    Kondo M; Murakawa Y; Moriyama M; Honda M; Sugiura T; Onoda K; Watanabe Y; Kakimaru H
    Mod Rheumatol; 2021 Jan; 31(1):88-93. PubMed ID: 32075469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of multiple hepatic lesions associated with methotrexate-associated lymphoproliferative disorder.
    Matsumoto R; Numata K; Doba N; Hara K; Chuma M; Fukuda H; Nozaki A; Tanaka K; Ishii Y; Maeda S
    J Med Ultrason (2001); 2016 Oct; 43(4):545-51. PubMed ID: 27577564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients.
    Kameda T; Dobashi H; Miyatake N; Inoo M; Onishi I; Kurata N; Mitsunaka H; Kawakami K; Fukumoto T; Susaki K; Izumikawa M; Nakashima S; Shimada H; Takeuchi Y; Haba R; Mano S; Onishi H; Imataki O; Matsunaga T
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1302-9. PubMed ID: 24515570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate-associated lymphoproliferative disorder with an osteolytic vertebral lesion in an elderly patient with rheumatoid arthritis: A case report.
    Hirata C; Kenzaka T; Akita H
    J Clin Pharm Ther; 2021 Aug; 46(4):1178-1181. PubMed ID: 33768586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.